Inhibrx Biosciences, Inc. Common Stock
Follow $INBX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $INBX by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is INBX moving today?
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
INBX overview
Related filings and maps
Congress activity in INBX
No receipt-qualified filings found.
INBX contract awards, year to date.
Public federal awards linked to this ticker.
INBX lobbying filings, year to date.
Registered lobbying filings matched to Inhibrx Biosciences, Inc. Common Stock.